RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992024-07-09T16:59:38+10:00

PARAGON-II | ACTRN12621000639820

PARAGON-II is a trial investigating whether a combination of two drugs (letrozole with alpelisib or letrozole with ribociclib) is an active treatment for a range of advanced gynaecological cancers that expresses hormone receptors.

PARAGON-II | ACTRN126210006398202024-07-09T17:00:40+10:00

ADELE | ACTRN12621000273886

ADELE is a randomised phase 2 trial testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer.  

ADELE | ACTRN126210002738862024-07-09T17:00:50+10:00

ENDO-3 | NCT04073706

ENDO-3 is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection. The outcomes from this trial will provide high-level evidence on sentinel lymph node [...]

ENDO-3 | NCT040737062024-07-09T17:00:57+10:00
Go to Top